Aspen Investment Management Inc Has $895,000 Holdings in AbbVie Inc. $ABBV

Aspen Investment Management Inc grew its position in AbbVie Inc. (NYSE:ABBV) by 6.4% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 4,823 shares of the company’s stock after buying an additional 290 shares during the quarter. Aspen Investment Management Inc’s holdings in AbbVie were worth $895,000 at the end of the most recent quarter.

Several other institutional investors have also made changes to their positions in ABBV. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie during the 2nd quarter valued at $25,000. TD Capital Management LLC boosted its position in shares of AbbVie by 82.9% in the first quarter. TD Capital Management LLC now owns 128 shares of the company’s stock worth $27,000 after buying an additional 58 shares during the period. Spurstone Advisory Services LLC purchased a new position in shares of AbbVie during the second quarter valued at $28,000. Financial Gravity Companies Inc. acquired a new position in AbbVie during the second quarter valued at $36,000. Finally, Bear Mountain Capital Inc. lifted its stake in AbbVie by 480.6% in the 2nd quarter. Bear Mountain Capital Inc. now owns 209 shares of the company’s stock worth $40,000 after acquiring an additional 173 shares in the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

AbbVie Price Performance

NYSE ABBV opened at $233.83 on Wednesday. AbbVie Inc. has a fifty-two week low of $163.81 and a fifty-two week high of $244.81. The stock’s 50-day moving average is $225.84 and its two-hundred day moving average is $204.57. The firm has a market cap of $413.27 billion, a P/E ratio of 111.35, a price-to-earnings-growth ratio of 1.42 and a beta of 0.50. The company has a debt-to-equity ratio of 44.14, a current ratio of 0.74 and a quick ratio of 0.61.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 699.66% and a net margin of 6.45%.The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the prior year, the firm posted $3.00 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. On average, analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. AbbVie’s dividend payout ratio is presently 524.24%.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on ABBV. Piper Sandler reaffirmed an “overweight” rating and set a $289.00 target price (up previously from $284.00) on shares of AbbVie in a research note on Wednesday, November 5th. Berenberg Bank raised shares of AbbVie from a “hold” rating to a “buy” rating and boosted their price objective for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. HSBC set a $225.00 price objective on shares of AbbVie in a research note on Thursday, October 2nd. Hsbc Global Res lowered shares of AbbVie from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 1st. Finally, Daiwa Capital Markets raised shares of AbbVie from a “neutral” rating to an “outperform” rating and set a $214.00 price target on the stock in a research note on Thursday, August 7th. Three equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $240.14.

AbbVie Company Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.